Quick Answer
Sionna Therapeutics, Inc. reported Net Income of -$75.27 million for fiscal year 2025.
Sionna Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net Income | -$75.27M -22.0% |
-$61.69M | — |
| Diluted EPS | -$1.88 +88.2% |
-$15.99 | — |
| Total Assets | $325.95M +75.5% |
$185.75M | — |
| Cash and Equivalents | $58.45M +54.7% |
$37.79M | — |
| Stockholders Equity | $306.83M +287.4% |
-$163.71M -42.5% |
-$114.88M |
| R&D Expense | $60.26M +5.2% |
$57.29M | — |
| Operating Income | -$88.98M -26.1% |
-$70.56M | — |
| Shares Outstanding | 44.72M +847.0% |
4.72M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$20.28M | +20.3% | -12.2% |
| Diluted EPS | September 30, 2025 | -$0.46 | +91.9% | +99.9% |
| Total Assets | September 30, 2025 | $339.27M | — | -3.6% |
| Cash and Equivalents | September 30, 2025 | $50.83M | +42.2% | +24.0% |
| Stockholders Equity | September 30, 2025 | $321.67M | +316.5% | -4.4% |
| R&D Expense | September 30, 2025 | $16.04M | -34.7% | +4.3% |
| Operating Income | September 30, 2025 | -$23.80M | +14.9% | -8.7% |
| Shares Outstanding | September 30, 2025 | 44.46M | — | +0.8% |
- Sionna Therapeutics, Inc. reported Net Income of -$75.27 million for fiscal year 2025.
- Sionna Therapeutics, Inc. showed a decrease of -22.0% in Net Income compared to the prior fiscal year.
- Sionna Therapeutics, Inc. reported Diluted EPS of $1.88 per share (loss) for fiscal year 2025.
- Sionna Therapeutics, Inc. showed an increase of +88.2% in Diluted EPS compared to the prior fiscal year.
- Sionna Therapeutics, Inc. reported Total Assets of $325.95 million for fiscal year 2025.
- Sionna Therapeutics, Inc. showed an increase of +75.5% in Total Assets compared to the prior fiscal year.
- Sionna Therapeutics, Inc. reported Cash and Equivalents of $58.45 million for fiscal year 2025.
- Sionna Therapeutics, Inc. showed an increase of +54.7% in Cash and Equivalents compared to the prior fiscal year.
- Sionna Therapeutics, Inc. reported Stockholders Equity of $306.83 million for fiscal year 2025.
- Sionna Therapeutics, Inc. showed an increase of +287.4% in Stockholders Equity compared to the prior fiscal year.
- Sionna Therapeutics, Inc. reported R&D Expense of $60.26 million for fiscal year 2025.
- Sionna Therapeutics, Inc. showed an increase of +5.2% in R&D Expense compared to the prior fiscal year.
- Sionna Therapeutics, Inc. reported Operating Income of -$88.98 million for fiscal year 2025.
- Sionna Therapeutics, Inc. showed a decrease of -26.1% in Operating Income compared to the prior fiscal year.
- Sionna Therapeutics, Inc. reported Shares Outstanding of 44.72 million shares for fiscal year 2025.
- Sionna Therapeutics, Inc. showed an increase of +847.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: